Already begin to arrive first results of clinical trials looking for a covid-19 vaccine. The magazine ‘The Lancet’ has just published the result of a study by the Beijing Institute of Biotechnology evaluating the safety and efficacy of a vaccine candidate drug. The first results, published just one month after starting the experiment, suggest that the compound manages to generate an immune response from 28 days after injection. These conclusions, still preliminary, are promising for further investigation. But they do not imply that we have already found the definitive vaccine. There is still a long way to go.
According to the World Health Organization (WHO), there are currently 10 vaccine candidates that are being tested in humans. And 114 more that continue to be validated in the laboratory. The results announced this Friday correspond to one of the first projects started and that, today, still in the first phase of investigation. The study had 108 participants between 18 and 60 years old, recruited in the Chinese city of Wuhan, epicenter of the pandemic. Each of them received a dose of the experimental compound and they subsequently went through regular medical check-ups and blood tests to see if the drug was working.
In the report published this Friday by those responsible for the study, it is indicated that this vaccine managed to generate a certain immune response after two weeks. And after 28 days it was observed that the majority of the participants had experienced a significant increased specific antibodies against SARS-CoV-2 and T cells, The two naturales natural barriers ’of the body to face a virus. At the same time, mild to moderate adverse effects were also recorded. These include pain at the injection site, fever, fatigue, headache, and muscle pain. A case of severe fever, shortness of breath and muscle breathing was also reported, which ceased after 48 hours. These results, therefore, would give rise to further investigation of this compound. In phase 2 of this same study, in fact, this same vaccine is being tested on 500 more people, which also include those over 60 years of age.
“We are far from a vaccine for everyone”
“These results should interpret with caution. The challenges in developing a covid-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from the virus. This result shows a promising vision for the development of vaccines, but We are still a long way from making this vaccine available to everyone.“warns Wei Chen, a researcher at the Beijing Institute of Biotechnology and responsible for this study, in a press release.
The results of this first trial are presented with their respective limitations. The sample of this first phase is small and the study period has been short, “which limits the ability to detect adverse reactions more rare for the vaccine or provide solid evidence of its ability to generate an immune reaction, “said those responsible for the study. The research report presented this Friday also reveals that the first phase of the trial has been completed, but that the answers more They will not arrive until December 30, 2020 (when the tests are expected to end.) Even then, we will have to wait until December 20, 2022 to conclude the study.